We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Based Tool Accelerates Detection of Kidney Cancer

By HospiMedica International staff writers
Posted on 26 Dec 2025

Diagnosing kidney cancer depends on computed tomography scans, often using contrast agents to reveal abnormalities in kidney structure. More...

Tumors are not always searched for deliberately, as many scans are performed for unrelated reasons such as trauma or abdominal pain, increasing the risk that early cancers are missed. At the same time, radiology faces a global shortage of specialists while imaging volumes continue to rise, placing growing pressure on already overstretched clinicians. Now, researchers have validated an artificial intelligence (AI) tool that supports radiologists by accelerating kidney cancer detection and improving consistency in image interpretation.

The machine-learning-based system, developed at the University of Tartu Institute of Computer Science (Tartu, Estonia), in collaboration with engineers from Better Medicine (Tartu, Estonia), is designed to assist radiologists in analyzing abdominal CT scans and identifying kidney lesions more efficiently. The tool, called BMVision, analyses CT images and highlights both malignant and benign kidney lesions. It is designed to function as a supportive second reader, helping clinicians interpret complex imaging data without replacing human expertise.

In a retrospective study to evaluate the effectiveness of the AI tool, six radiologists reviewed 200 CT scans, both with and without AI assistance, resulting in 2,400 individual image readings. The assessments compared diagnostic sensitivity, tumor measurement accuracy, reporting speed, and agreement between radiologists. The findings, published in Nature Communications Medicine, showed that AI assistance reduced the time required to identify, measure, and report malignant lesions by approximately one third, while maintaining diagnostic accuracy.

“This study adds to the growing body of evidence that modern AI tools developed in research labs can make a real impact in clinical practice and support doctors in their daily work,” said Associate Professor Dmytro Fishman. “We are very encouraged by these results, which show that AI research in medicine is not only meaningful, but it can truly be used for good.”

Related Links:
University of Tartu Institute of Computer Science
Better Medicine


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Desk Aneroid Sphyg
Diagnostix 750D+
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.